These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 30196504)

  • 1. Expression of IgG Monoclonals with Engineered Immune Effector Functions.
    Vazquez-Lombardi R; Nevoltris D; Rouet R; Christ D
    Methods Mol Biol; 2018; 1827():313-334. PubMed ID: 30196504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgG Fc engineering to modulate antibody effector functions.
    Wang X; Mathieu M; Brezski RJ
    Protein Cell; 2018 Jan; 9(1):63-73. PubMed ID: 28986820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient expression of human antibodies in mammalian cells.
    Vazquez-Lombardi R; Nevoltris D; Luthra A; Schofield P; Zimmermann C; Christ D
    Nat Protoc; 2018 Jan; 13(1):99-117. PubMed ID: 29240734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity.
    Kellner C; Derer S; Klausz K; Rosskopf S; Wirt T; Rösner T; Otte A; Cappuzzello E; Peipp M
    Methods Mol Biol; 2018; 1827():381-397. PubMed ID: 30196508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methods to engineer and identify IgG1 variants with improved FcRn binding or effector function.
    Kelley RF; Meng YG
    Methods Mol Biol; 2012; 901():277-93. PubMed ID: 22723108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
    Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
    Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.
    Arduin E; Arora S; Bamert PR; Kuiper T; Popp S; Geisse S; Grau R; Calzascia T; Zenke G; Kovarik J
    Mol Immunol; 2015 Feb; 63(2):456-63. PubMed ID: 25451975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced elimination of IgG antibodies by engineering the variable region.
    Igawa T; Tsunoda H; Tachibana T; Maeda A; Mimoto F; Moriyama C; Nanami M; Sekimori Y; Nabuchi Y; Aso Y; Hattori K
    Protein Eng Des Sel; 2010 May; 23(5):385-92. PubMed ID: 20159773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C; Brünker P; Suter T; Moser S; Püntener U; Umaña P
    Biotechnol Bioeng; 2006 Apr; 93(5):851-61. PubMed ID: 16435400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse.
    Wawrzynczak EJ; Denham S; Parnell GD; Cumber AJ; Jones PT; Winter G
    Mol Immunol; 1992 Feb; 29(2):221-7. PubMed ID: 1542299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A stable engineered human IgG3 antibody with decreased aggregation during antibody expression and low pH stress.
    Saito S; Namisaki H; Hiraishi K; Takahashi N; Iida S
    Protein Sci; 2019 May; 28(5):900-909. PubMed ID: 30834577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural analysis of Fc/FcγR complexes: a blueprint for antibody design.
    Caaveiro JM; Kiyoshi M; Tsumoto K
    Immunol Rev; 2015 Nov; 268(1):201-21. PubMed ID: 26497522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.
    Chen TF; Sazinsky SL; Houde D; DiLillo DJ; Bird J; Li KK; Cheng GT; Qiu H; Engen JR; Ravetch JV; Wittrup KD
    J Mol Biol; 2017 Aug; 429(16):2528-2541. PubMed ID: 28694069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S; Kellner C; Berger S; Valerius T; Peipp M
    Methods Mol Biol; 2012; 907():519-36. PubMed ID: 22907372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
    Kelton W; Mehta N; Charab W; Lee J; Lee CH; Kojima T; Kang TH; Georgiou G
    Chem Biol; 2014 Dec; 21(12):1603-9. PubMed ID: 25500223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
    Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
    Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
    White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
    Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.